FDA Approves New Nasal Spray to Reverse Overdoses

To be sold as Opvee, the spray contains the medication nalmefene hydrochloride and will be available with a prescription

opvee overdose nasal spray
Source: Indivior

TUESDAY, May 23, 2023 (HealthDay News) -- The U.S. Food and Drug Administration on Monday approved a second nasal spray for reversing an opioid overdose.

To be sold as Opvee, the spray contains the medication nalmefene hydrochloride and will be available to Americans aged 12 and older with a prescription, the FDA said.

"The agency continues to advance the FDA Overdose Prevention Framework and take actionable steps that encourage harm reduction by supporting the development of novel overdose reversal products," FDA Commissioner Robert Califf, M.D., said in an agency news release. "On the heels of the FDA's recent approval of the first over-the-counter opioid reversal agent [Narcan], the availability of nalmefene nasal spray places a new prescription opioid reversal option in the hands of communities, harm reduction groups, and emergency responders."

Indivior, which will make and sell Opvee going forward, said the spray should be available by October. Indivior bought Opiant Pharmaceuticals, which developed Opvee, in March.

"Opvee's FDA approval represents a significant achievement in the development of new treatment options to address today's era of opioid overdoses that are driven by powerful synthetic opioids, such as fentanyl," Indivior CEO Mark Crossley said in a company news release. "Opvee is an emergency treatment for the fast reversal of respiratory depression triggered by natural or synthetic opioids, including fentanyl, and we are committed to making this novel rescue medication widely available to those who need it most to help save lives."

"The approval of Opvee was supported by safety and pharmacokinetic studies, as well as a study in people who use opioids recreationally to assess how quickly the drug works," according to the FDA. Adverse reactions included nasal discomfort, headache, nausea, dizziness, hot flush, vomiting, anxiety, fatigue, nasal congestion and throat irritation, pain in the nose, decreased appetite, skin redness, and excessive sweating, the FDA said in its approval notice. Using the medication can also trigger a wide range of opioid withdrawal symptoms, from diarrhea to rapid heart rate to increased blood pressure and more.

More Information

Physician’s Briefing Staff

Physician’s Briefing Staff

Published on May 23, 2023

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ